At a glance
- Originator Novartis
- Class Analgesics; Anti-inflammatories; Antipyretics; Antirheumatics; Piperazines
- Mechanism of Action Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 02 Jun 1995 Discontinued-Preclinical for Rheumatic disorders in Switzerland (Unknown route)